The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Genomic Biomarker Market From 2026 To 2030?
The genomic biomarker market size has seen rapid expansion in recent years. It is anticipated to increase from $9.9 billion in 2025 to $11.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.8%. The growth observed in the preceding period can be attributed to several factors, including heightened investment in genomic research, an increase in oncology-centric biomarker studies, the growing availability of next-generation sequencing technologies, strengthening collaboration between diagnostics and pharmaceutical companies, and the initial uptake of personalized medicine approaches.
The genomic biomarker market size is anticipated to undergo significant expansion in the coming years, projected to reach $22.23 billion by 2030 with a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is driven by factors such as the increasing demand for precision medicine therapies, the growing utilization of biomarkers in drug development, the wider adoption of companion diagnostics, an intensified focus on early disease detection, and increasing regulatory support for approvals reliant on biomarkers. Prominent trends expected in this period include the rising adoption of predictive genomic biomarkers, increased use of pharmacogenomic testing, greater integration of genomic data into clinical decision-making, the expansion of biomarker-based oncology diagnostics, and a strengthened emphasis on clinical validation standards.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp
What Drivers Are Influencing The Genomic Biomarker Market?
The genomic biomarker market is projected to expand significantly due to the rising incidence of chronic diseases. These are long-term health conditions that endure over time and often progress slowly. The increasing occurrence of chronic diseases can be attributed to aging populations and growing rates of lifestyle-related conditions like obesity and diabetes. Genomic biomarkers facilitate early detection and personalized prevention strategies for chronic diseases by pinpointing genetic predispositions and customizing interventions. This forward-looking approach helps mitigate prevalence by targeting individuals at risk before disease manifestation. For instance, in September 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported 41 million deaths worldwide each year, representing 74% of all fatalities linked to chronic diseases. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the escalating prevalence of chronic diseases is a key driver for the growth of genomic biomarkers.
Which Segments Are Included In The Analysis Of The Genomic Biomarker Market?
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
Which Trends Are Impacting The Growth Of The Genomic Biomarker Market?
Leading enterprises within the genomic biomarker market are concentrating on developing sophisticated products, such as advanced liquid biopsy assays, to facilitate comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic test that analyzes genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. Identifying genomic biomarkers can provide information about specific mutations, gene expression profiles, or other genetic alterations associated with cancer. For instance, in November 2023, Illumina Inc., a US-based biotechnology company, launched an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), intended for comprehensive genomic profiling of solid tumors. This assay delivers enhanced analytical sensitivity by detecting low-frequency variants with just 20 ng of cell-free DNA, a reduction from 30 ng. It provides results in under four days, substantially accelerating genomic profiling compared to traditional methods. The streamlined workflow and upcoming automation are set to simplify lab integration and boost efficiency.
Which Key Industry Participants Are Active In The Genomic Biomarker Market?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
Read the full genomic biomarker market report here:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Genomic Biomarker Market?
North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Genomic Biomarker Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20557&type=smp
Browse Through More Reports Similar to the Global Genomic Biomarker Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Renal Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model